Updated: Sep 22, 2020
As of 5th Sep 2020, the impact of covid19 virus has been severe worldwide and more than 879 thousands deaths were recorded i.e. approx. 3.28% of the total infected corona-virus cases globally. Covid19 has also brought economic distress where many top developed & developing countries have faced negative GDP growth in the last quarter (excluding China). Currently, some of the covid19 vaccines clinical trials are in phase 3. However Russian government has approved one covid19 vaccine Sputnik-V on 11th Aug 2020, developed by Gamaleya Research Institute in Moscow, without phase 3 clinical trials which is matter of concern according to experts.
In various researches on covid19 cases in different countries like USA, UK, Italy, Brazil, India, etc., it was found that more than 30% of the deaths of in-hospitals covid19 patients were diabetic patients too. Covid19 virus has affected the diabetic patients in more critical conditions. The impact of covid19 virus for type 1 and type 2 diabetes were also different, and the most affected & deaths were for type 2 diabetic covid19 cases. The covid19 has also increased the market consumption for anti-diabetic drugs to control the blood glucose level in body for diabetic patients. However, in some countries where there is financial distress for mass population, the unemployment, and local supply issues of medications have cut down cost by skipping diabetes tests and diabetic drug doses.
Currently there are more than 463 million people globally are diabetic, and China accounts the highest number (more than 120 million), followed by India (more than 70 million), and United States (more than 34 million). About 20-25% of the diabetic cases are not diagnosed because of the late symptoms or no tests. In this pandemic situation, anti-diabetic drugs supply and care is essential and requires uninterrupted accessibility to diabetic patients. During the pandemic, the lifestyle and daily routine for most of the people has also changed, and could impact their glycemia.
There are different types of drug class available for diabetes which could be either oral anti-diabetic drugs or injectable drugs. Insulin drug class accounted the highest market share (~35%) in 2019 among the other drug class types Biguanides (metformin), Sulfonylureas (glimepiride), Meglitinides (repaglinide), Thiazolidinediones (pioglitazone), Dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin), α-Glucosidase inhibitors (acarbose), etc. Among oral anti-diabetic drugs, Metformin accounts the highest market share followed by Sulfonylureas. By route of administration, the oral anti-diabetic drugs market growth is higher compared to injectable drugs. Combination drugs market for diabetes is also estimated to have a CAGR of 10.87% over the forecast period. Combination drugs consists of two or three different active pharmaceutical ingredients to serve the more than one causes of diabetes in patients and convenient too for intake either through oral or by insulin combination. Metformin is also used as combination drugs with pigolitazone, or glimepiride or sitagliptin, etc.
By region, North America accounts the highest market share in anti-diabetic drugs market because of the higher spending on diabetes healthcare. The market for anti-diabetic drugs in Asia-pacific region is expected to have the highest growth rate 13.1% over the forecast period 2020-2025. In the region, China, India and South-east Asian countries will drive the market because of the high increase in diabetic symptoms in mass population, awareness, and increasing expenditure on healthcare. Only India & China together accounts more than 190 million of diabetes population.
The key players in the market includes Novo Nordisk, Sanofi, AstraZeneca, Boehringer Ingelheim, Pfizer, Merck & Co., Eli Lilly and Company, Biocon, Novartis, Teva Pharmaceuticals, Takeda Pharmaceutical, etc. Novo Nordisk is currently the leading player in this market.
Global Anti-diabetes Drugs Market Key Highlights:
Segmented by Drug Class Type, Route of Administration, Application, and Geography
Base Year: 2019, Estimated Year: 2020, Forecast: 2021-25 (Y-o-Y)
Historical Years: 2014-2018
Market Share for 2019 & 2020 (est.) and Recent developments
Regions: 5 (NA, SA, EU, APAC, MEA)
Country: 19 Major Countries + Rest of Countries in Each Region
Company Profiles: 12+ Major Companies